American Oncology Institute (AOI) Hyderabad First in Telangana to Treat Patients with Ethos Integrated Adaptive Radiotherapy & SGRT

▴ American Oncology Institute
y precisely targeting tumors and minimizing radiation exposure to healthy tissues, patients experience fewer side effects, leading to improved quality of life during and after treatment. The reduced treatment times also allow patients to spend less time on the couch thus minimizing movement during treatment."

Hyderabad, 11th March 2024 – In a pioneering move in Telangana, American Oncology Institute (AOI), one of the largest cancer chain hospitals in South Asia, has successfully treated cervix and prostate cancer patients using Ethos and SGRT while solidifying its position as a leader in advanced cancer care solutions. AOI Hyderabad now provides patients access to state-of-the-art technology, leading to improved treatment outcomes and an elevated quality of life.

Ethos an AI-driven holistic solution integrated with Varian’s most advanced surface guidance system, IDENTIFY™ technology, signifies a revolutionary advancement in precision cancer care. SGRT technology uses advanced 3D thermal camera technology, enabling real-time monitoring and tracking of patient positioning and motion during radiotherapy sessions, ensuring precise delivery of radiation to the tumor while minimizing exposure to surrounding healthy tissues. By integrating SGRT with Adaptive Ethos Radiotherapy, AOI enhances treatment accuracy and efficacy, resulting in improved outcomes and reduced side effects for cancer patients.

Dr Prabhakar P, Regional Chief Operating Officer (RCOO) of AOI, expressed his enthusiasm about this milestone, stating, "Radiotherapy technology has advanced quickly in recent years, the Indian radiotherapy market is projected to increase from $126 million in 2022 to $250 million in 2030, at a CAGR of 9 per cent. Using artificial intelligence (AI), advancements in radiotherapy can enhance accessibility and efficiency. AI can improve treatment precision, minimize side effects, and optimize resource distribution through AI-driven treatment planning, precise dosage calculation, and real-time tumor tracking. We at AOI, are the first to combine both technologies to ensure best outcome and quality of life for the patients in Telangana. Integrating SGRT with Adaptive Ethos Radiotherapy represents a paradigm shift in cancer treatment."

Dr Vinitha Reddy, Radiation Oncologist at AOI Hyderabad, highlighted the benefits of this integration for patients, saying, "The growing acceptance and recognition of Surface Guided Radiation Therapy (SGRT) as a promising imaging technique has supported its recent installation in a large number of radiation oncology facilities. The integration of SGRT and Ethos signifies a pioneering advancement in radiation therapy, epitomizing the future of precision treatment methods. With Adaptive AI-based technology at its core, we are at the forefront of revolutionizing radiation therapy. We provide patients with a superior treatment experience, minimizing disruptions to their daily lives. By precisely targeting tumors and minimizing radiation exposure to healthy tissues, patients experience fewer side effects, leading to improved quality of life during and after treatment. The reduced treatment times also allow patients to spend less time on the couch thus minimizing movement during treatment."

In terms of patient positioning, SGRT is an effective tool for the reduction of the overall treatment time and minimizing of imaging dose. It provides in-room online information of the complete surface and position of the patient. For superficial tumors, SGRT allows for a more accurate positioning compared to 3-point-lasers and might allow to reduce the number of daily imaging in some cases.

American Oncology Institute is the leading cancer hospital chain in South Asia operating 16 cancer hospitals in the region. AOI founded in 2012 by a group of physicians and industry experts, is today a wholly owned subsidiary of the largest cancer medical technology company - Varian Medical Systems, a Siemens Healthineers Company.

Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Why AstraZeneca is Withdrawing the Covid-19 Vaccine Globally: Explained May 13, 2024
Achieving Healthier Lifestyles: Understanding India's New Dietary GuidelinesMay 11, 2024
The Link Between Childhood Sleep and Adult Psychosis: A Critical AnalysisMay 11, 2024
Uncovering Immunization Gaps: Insights into Measles Vaccination Challenges in IndiaMay 11, 2024
Unlocking New Horizons: Gene Therapies for Hearing Loss and BlindnessMay 10, 2024
Kerala Health Alert: West Nile Fever Cases Confirmed in Thrissur, Malappuram, and KozhikodeMay 10, 2024
Managing Health in the Heat: Demand for Medications Surges in IndiaMay 10, 2024
Sudhamukti Ayurvedic Medicine by OJSP: A New Era in Diabetes ManagementMay 10, 2024
The Role of Genetic Profiles in Alzheimer’s Therapy: APOE4 and Treatment ResponsesMay 08, 2024
Assessing Covishield Safety: Indian Research Offers Reassurance Amidst Rare Side Effect DiscussionsMay 08, 2024
Quadria Capital Invests $102 Million in NephroPlus to Boost Dialysis Services Across AsiaMay 08, 2024
Reducing Stigma, One Story at a Time: Media's Role in Mental HealthMay 07, 2024
When Your Body Makes Beer: Exploring the Curious Case of Auto-Brewery SyndromeMay 07, 2024
Hair Today, Gone Tomorrow: Why Guys Go Bald Before Marriage May 07, 2024
Menopausal Transitions and Mental Health: UCL Study Highlights Increased Depression RiskMay 07, 2024
Vasavi Club of Buddhapurnima organised #GoVote, a vote awareness driveMay 06, 2024
Vasavi Club of Buddhapurnima organised #GoVote, a vote awareness driveMay 06, 2024
Harnessing AI for Early Alzheimer's Disease Diagnosis: IIT Indore's BreakthroughMay 06, 2024
Aurobindo Pharma's Bhiwadi Facility Under FDA Scrutiny: Understanding the ObservationsMay 06, 2024
Exploring the Role of Mediator Protein Complex in Cell Division: Implications for Disease ManagementMay 06, 2024